改良Ottawa评分用于识别癌症相关孤立性远端深静脉血栓形成中更适合延长抗凝治疗候选者的效用:来自ONCO DVT研究的启示
该研究为ONCO DVT研究的事后亚组分析,按改良Ottawa评分将601例癌症相关孤立性远端深静脉血栓形成患者分为低(≤-1分,126例)、中(0分,323例)、高(≥1分,152例)评分亚组,比较12个月与3个月艾多沙班治疗的临床结局。结果显示,中、高评分亚组中12个月治疗的症状性复发性静脉血栓栓塞或静脉血栓栓塞相关死亡累积发生率低于3个月治疗,低评分亚组两组无差异,且各亚组大出血累积发生率均无显著差异。
要点
- 中评分(0分)亚组12个月vs 3个月艾多沙班治疗的症状性复发性VTE或VTE相关死亡累积发生率为0.8% vs 7.6%。
- 高评分(≥1分)亚组上述结局12个月vs 3个月为3.1% vs 15.6%,低评分(≤-1分)亚组为0.0% vs 2.2%。
- 低、中、高评分亚组12个月vs 3个月的大出血累积发生率分别为10.1% vs 7.6%、8.8% vs 5.0%、13.9% vs 12.6%,均无显著差异。
核心结论
- 在癌症相关孤立性远端深静脉血栓形成患者中,与3个月艾多沙班治疗相比,12个月治疗在中、高改良Ottawa评分亚组显示较低的血栓事件风险,但在低评分亚组未显示,提示低改良Ottawa评分患者延长抗凝治疗超过3个月的获益有限。
研究设计与样本
- ONCO DVT研究的事后亚组分析,将601例患者按改良Ottawa评分分为低(≤-1分,126例)、中(0分,323例)、高(≥1分,152例)三个亚组,比较12个月与3个月艾多沙班治疗组的临床结局。
主要发现
- 低评分亚组12个月vs 3个月艾多沙班治疗的症状性复发性静脉血栓栓塞或静脉血栓栓塞相关死亡累积发生率为0.0% vs 2.2%,两组无差异。
- 中评分亚组上述结局12个月vs 3个月为0.8% vs 7.6%,高评分亚组为3.1% vs 15.6%,12个月治疗组均低于3个月治疗组。
- 低评分亚组12个月vs 3个月的大出血累积发生率为10.1% vs 7.6%,中评分为8.8% vs 5.0%,高评分为13.9% vs 12.6%,均无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The ONCO DVT study (Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis) revealed superiority of 12-month relative to 3-month edoxaban treatment for the thrombotic risk in cancer-associated isolated distal deep vein thrombosis. However, it is unknown whether the superiority could be common in different modified Ottawa score subgroups. OBJECTIVES: To identify more preferable candidates for extended anticoagulation in patients with cancer-associated isolated distal deep vein thrombosis using the modified Ottawa score. METHODS: In this post-hoc subgroup analysis of the ONCO DVT study, we stratified 601 patients into the low (≤-1, N = 126), intermediate (0, N = 323), and high (≥1, N = 152) modified Ottawa score subgroups and compared clinical outcomes between the 12-month and 3-month edoxaban treatment groups. RESULTS: The cumulative incidence of symptomatic recurrent venous thromboembolism or venous thromboembolism-related death was not different between the 12-month and 3-month edoxaban treatment groups in the low score subgroup (0.0% vs 2.2%), whereas it was lower in the 12-month than in the 3-month edoxaban treatment group in the intermediate (0.8% vs 7.6%) and high (3.1% vs 15.6%) score subgroups. There were no significant differences in the cumulative incidences of the major bleeding between the 12-month and 3-month edoxaban treatment groups in the low (10.1% vs 7.6%), intermediate (8.8% vs 5.0%), and high (13.9% vs 12.6%) score subgroups. CONCLUSION: A 12-month compared with 3-month edoxaban treatment showed a lower risk of thrombotic events in patients with cancer-associated isolated distal deep vein thrombosis in the intermediate and high modified Ottawa score subgroups but not in the low score subgroup, suggesting a limited benefit of extended anticoagulation therapy beyond 3 months in patients with low modified Ottawa score.
引用
- Xiong W, Yamashita Y, Morimoto T, et al. Utility of the modified Ottawa score for identification of more preferable candidates of extended anticoagulation therapy in cancer-associated isolated distal deep vein thrombosis: insight from the ONCO DVT Study. J Thromb Haemost. 2024. PMID: 39284385. doi:10.1016/j.jtha.2024.09.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。